NASDAQ · XRTX
XORTX Therapeutics financials
$1.70−0.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$2.7M | -$3.1M | -$2.4M | -$6.9M | -$2.9M |
| Net income | -$2.7M | -$3.3M | -$2.2M | -$7.7M | -$1.6M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.56 | $-1.15 | $-1.09 | $-5.22 | $-1.44 |
| EBITDA | -$2.6M | -$3.0M | -$2.3M | -$6.8M | -$2.9M |
| Operating cash flow | -$2.8M | -$3.7M | -$6.6M | -$8.2M | -$4.8M |
| Free cash flow | -$2.8M | -$3.7M | -$6.6M | -$8.2M | -$4.8M |
| Diluted shares | 4.7M | 2.9M | 2.0M | 1.5M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $864.5K | $2.5M | $3.4M | $10.4M | $14.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $2.7M | $4.1M | $5.5M | $12.4M | $17.4M |
| Total liabilities | $599.1K | $758.0K | $825.9K | $5.4M | $4.2M |
| Shareholders' equity | $2.1M | $3.3M | $4.6M | $7.0M | $13.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology